Edition:
United Kingdom

Abeona Therapeutics Inc (ABEO.OQ)

ABEO.OQ on NASDAQ Stock Exchange Capital Market

4.43USD
24 Jun 2019
Change (% chg)

-- (--)
Prev Close
$4.43
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
133,652
52-wk High
$17.25
52-wk Low
$4.41

Latest Key Developments (Source: Significant Developments)

Abeona Therapeutics Receives FDA Fast Track Designation For ABO-202 AAV9 Gene Therapy In CLN1 Disease
Tuesday, 18 Jun 2019 

June 18 (Reuters) - Abeona Therapeutics Inc ::ABEONA THERAPEUTICS RECEIVES FDA FAST TRACK DESIGNATION FOR ABO-202 AAV9 GENE THERAPY IN CLN1 DISEASE.ABEONA THERAPEUTICS INC - ABEONA IS PREPARING TO INITIATE A PHASE 1/2 CLINICAL TRIAL EVALUATING ABO-202 IN PATIENTS WITH CLN1 DISEASE.ABEONA THERAPEUTICS INC - WILL PROVIDE GUIDANCE ON TIMING OF TRIAL LATER THIS YEAR..  Full Article

Abeona Therapeutics Appoints João Siffert Chief Executive Officer
Monday, 11 Feb 2019 

Feb 11 (Reuters) - Abeona Therapeutics Inc ::ABEONA THERAPEUTICS APPOINTS JOÃO SIFFERT, M.D. CHIEF EXECUTIVE OFFICER.ABEONA THERAPEUTICS INC - SIFFERT HAS SERVED AS INTERIM CEO SINCE NOVEMBER OF LAST YEAR..ABEONA THERAPEUTICS INC - SIFFERT WILL RETAIN HIS RESPONSIBILITIES AS HEAD OF RESEARCH AND DEVELOPMENT AND CMO UNTIL A CLINICAL DEVELOPMENT LEAD IS IDENTIFIED..  Full Article

VOGO And ABEO Sign Partnership Agreement To Deliver New Service Offering For Abeo’S Clients
Monday, 21 Jan 2019 

Jan 21 (Reuters) - VOGO SAS ::ABEO AND VOGO SIGN PARTNERSHIP AGREEMENT.ABEO AND VOGO ARE COMBINING THEIR EXPERTISE TO DELIVER A NEW SERVICE OFFERING FOR ABEO’S CLIENTS.NEW SOLUTION, WHICH IS TO UNDERGO COMMERCIAL VALIDATION IN THE FIRST HALF OF 2019, COULD ULTIMATELY PAVE THE WAY TO AN INTERNATIONAL DISTRIBUTION AGREEMENT.  Full Article

Abeona Therapeutics Appoints Christine Silverstein CFO
Tuesday, 8 Jan 2019 

Jan 8 (Reuters) - Abeona Therapeutics Inc ::ABEONA THERAPEUTICS STRENGTHENS FINANCIAL LEADERSHIP WITH NEW EXECUTIVE APPOINTMENTS.ABEONA THERAPEUTICS INC - HAS APPOINTED CHRISTINE SILVERSTEIN TO POSITION OF CHIEF FINANCIAL OFFICER.  Full Article

Abeona Unveils New Cystic Fibrosis Program
Thursday, 6 Dec 2018 

Dec 6 (Reuters) - Abeona Therapeutics Inc ::ABEONA THERAPEUTICS DETAILS PATHWAY FOR ADVANCING LEAD CLINICAL PROGRAMS AND UNVEILS NEW CYSTIC FIBROSIS PROGRAM BORN FROM NEXT GENERATION AIM™ VECTOR PLATFORM AT 2018 RESEARCH AND DEVELOPMENT DAY.ABEONA THERAPEUTICS INC - EXPANDING PHASE I/II STUDY OF ABO-102 FOR SANFILIPPO SYNDROME TYPE A (MPS IIIA).ABEONA THERAPEUTICS INC - PLANS TO AMEND ITS ONGOING PHASE I/II TRIAL EVALUATING ABO-102 FOR MPS IIIA TO ENROLL PATIENTS AT EARLIER STAGES OF DISEASE.ABEONA THERAPEUTICS INC - ABO-102 HAS BEEN WELL TOLERATED TO DATE WITH NO SERIOUS DRUG-RELATED ADVERSE EVENTS.ABEONA THERAPEUTICS INC - ESTABLISHED GMP MANUFACTURING CAPABILITY FOR EB-101 AT ITS GENE THERAPY MANUFACTURING FACILITY IN CLEVELAND.ABEONA THERAPEUTICS - FACILITY IN CLEVELAND HAS SCALABLE CAPACITY TO SUPPORT POTENTIAL COMMERCIAL LAUNCH OF EB-101.ABEONA THERAPEUTICS INC - EXPECTS TO INITIATE A PIVOTAL CLINICAL TRIAL EVALUATING POTENTIAL OF EB-101 FOR TREATMENT OF RDEB IN MIDDLE OF 2019.  Full Article

Abeona Therapeutics And Regenxbio Announce License Agreement
Monday, 5 Nov 2018 

Nov 5 (Reuters) - Abeona Therapeutics Inc ::ABEONA THERAPEUTICS AND REGENXBIO ANNOUNCE WORLDWIDE EXCLUSIVE LICENSES FOR THE TREATMENT OF FOUR RARE LYSOSOMAL STORAGE DISORDERS USING NAV AAV9 VECTOR.ABEONA THERAPEUTICS INC - ABEONA TO PAY REGENXBIO $20 MILLION UPFRONT.ABEONA THERAPEUTICS INC - ABEONA TO PAY REGENXBIO $10 MILLION PAID UPON SIGNING, $10 MILLION BY FIRST ANNIVERSARY OF AGREEMENT.ABEONA THERAPEUTICS INC - ANNUAL PAYMENTS OF $20 MILLION GUARANTEED PAYABLE UPON SECOND ANNIVERSARY OF AGREEMENT.  Full Article

Abeona Therapeutics Appoints Carsten Thiel As Chief Executive Officer
Monday, 2 Apr 2018 

April 2 (Reuters) - Abeona Therapeutics Inc ::APPOINTS CARSTEN THIEL, PH.D., AS CHIEF EXECUTIVE OFFICER.TIMOTHY J. MILLER WILL REMAIN PRESIDENT AND ASSUME POSITION OF CHIEF SCIENTIFIC OFFICER.  Full Article

Abeona Therapeutics Appoints Carsten Thiel, Ph.D., As Chief Executive Officer
Monday, 2 Apr 2018 

April 2 (Reuters) - Abeona Therapeutics Inc ::ABEONA THERAPEUTICS APPOINTS CARSTEN THIEL, PH.D., AS CHIEF EXECUTIVE OFFICER.TIM MILLER CONTINUES AS PRESIDENT AND ASSUMES CHIEF SCIENTIFIC OFFICER ROLE.THIEL MOST RECENTLY SERVED AS EXECUTIVE VICE PRESIDENT AND CHIEF COMMERCIAL OFFICER OF ALEXION PHARMACEUTICALS, INC.  Full Article

Abeona Therapeutics Reports Q4 Loss Per Share $0.19
Friday, 16 Mar 2018 

March 16 (Reuters) - Abeona Therapeutics Inc ::ABEONA THERAPEUTICS REPORTS FOURTH QUARTER 2017 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS.Q4 LOSS PER SHARE $0.19.Q4 REVENUE $215,000 VERSUS I/B/E/S VIEW $244,000.Q4 EARNINGS PER SHARE VIEW $-0.14 -- THOMSON REUTERS I/B/E/S.  Full Article

Abeona Receives FDA Rare Pediatric Disease Designation For ABO-202 Gene Therapy Program In CLN1 Disease
Thursday, 15 Mar 2018 

March 15 (Reuters) - Abeona Therapeutics Inc ::ABEONA THERAPEUTICS RECEIVES FDA RARE PEDIATRIC DISEASE DESIGNATION FOR ABO-202 GENE THERAPY PROGRAM IN CLN1 DISEASE.ABEONA THERAPEUTICS - FDA GRANTED RARE PEDIATRIC DISEASE DESIGNATION FOR ABO-202 PROGRAM, AN AAV-BASED GENE THERAPY FOR TREATMENT OF CLN1 DISEASE.  Full Article